



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Transdermal delivery of an antipsychotic drug using Nano-carriers

A Thesis

Submitted in Partial Fulfillment of the Requirements for the

Master degree
In Pharmaceutical Sciences
(Pharmaceutics)

By

Fatma Sa'eed Mostafa Mohamed

Bachelor of Pharmaceutical Sciences, 2013
Faculty of Pharmacy, Ain Shams University

Under Supervision of

Dr. Ahmed Shawky Geneidi, Ph.D
Professor of Pharmaceutics and Industrial pharmacy,
Faculty of Pharmacy, Ain Shams University

Dr. El-Sayed Abd El Ghany El-Sayed, Ph.D
Professor of Pharmaceutics and Industrial pharmacy,
Faculty of Pharmacy, Badr University in Cairo

Dr. Mona Mohamed Ahmed Abdel-Mottaleb, Ph.D
Associate Professor of Pharmaceutics and Industrial pharmacy,
Faculty of Pharmacy, Ain Shams University

2021

Acknowledgments

Throughout the working and writing of this thesis I have received a great deal of support and assistance.

At the beginning, my deepest gratitude goes to Allah for giving me the strength to accomplish this thesis with all the difficulties and triumphs I experienced. And I pray to Allah to accept it as a good deed.

I would like to thank my professors and supervisors without whom I would not have been able to complete this research and without whom I would not have made it through my master's degree!

My deep sincere indebtedness are first addressed to the late Professor **Ahmed Shawky Geneidi**, Professor of pharmaceuticals, Faculty of Pharmacy, Ain Shams University, may Allah bless his soul who passed away at the beginning of this work but I will never forget his infinite support and continuous encouragement during my very first steps in the research career.

My great appreciation to Professor **El-Sayed Abdel-Ghany El-Sayed** , Professor of pharmaceuticals, Faculty of Pharmacy, Badr University in Cairo, for his continuous support, great encouragement, and sincere suggestions throughout the development of this work.

My deepest indebtedness, respect and great appreciation to Associate Professor **Mona M.A. Abdel-Mottaleb**, Associate Professor of pharmaceuticals, Faculty of Pharmacy, Ain Shams University, I was lucky to have her as supervisor throughout my postgraduate career and I will never be able to describe how much I learned from her valuable instructions, whole-hearted guidance, patience and continuous encouragement.

Acknowledgments

Special thanks to Professor **Mohammad EL-Shanawany**, Dean of Faculty of Pharmacy, Badr University in Cairo for helping and supporting me throughout the different stages of this work.

Furthermore, many thanks for all my colleagues and friends in Faculty of Pharmacy, Badr University in Cairo for their precious support and friendship.

At last and most important, my family whom without them nothing would have really been achieved, My Great Parents (Mother and father): “thank you both for your help, patience and continuous support and for taking care of me and my son all the time”. My sister, who has been my backbone: “thank you for your hard-times supporter”. Nevertheless, I will always be grateful and never forget how my husband stood beside me, encouraged me in every step of the thesis. He has been a great support, and a great father for our son. Finally, my little son: “Thanks God for your presence, I love you”.

اللهم لك الحمد و المنة و الفضل

Fatma Sa'eed

List of contents

List of Abbreviations	V
List of Tables	VI
List of Figures	VIII
Abstract	XI
General Introduction	1
1. Schizophrenia.....	1
1.1. Introduction	1
1.2. Pathophysiology	2
1.3. Symptoms	5
1.4. Treatment protocols	7
1.5. Side effects of oral antipsychotics.....	13
1.6. Challenges against effective treatment of schizophrenia	14
2. Second generation Antipsychotics	16
2.1. Advantages of second generation antipsychotics over first generation antipsychotics	16
2.2. Transdermal formulations of second generation antipsychotics in literature.....	17
3. Lipid nanocarriers	26
Scope of Work	31
Chapter I: Preparation and evaluation of asenapine maleate loaded lipid nanocapsules.	
Introduction.....	33
Materials and Methods.....	42
Materials:	42
Equipment:	42
Methodology:	43
1. Determination of wavelength of maximum absorbance (λ_{max})	43
2. Construction of the calibration curve of asenapine maleate in methanol and in phosphate buffer solution pH (7.4) containing 2% Tween 80 (release media) using spectrophotometric assay	44

3. Construction of the Calibration curve of asenapine maleate in phosphate buffer solution pH (7.4) containing 2% Tween 80 (release media) using RP-HPLC assay	44
4. Preparation of blank and asenapine maleate loaded LNCs.....	45
5. Characterization of the prepared LNCs.....	47
5.1. Measurement of particle size and poly dispersity index (PDI)	47
5.2. Determination of Zeta potential.....	48
5.3. Determination of drug content in asenapine maleate loaded LNCs.....	48
6. Ex vivo skin permeation/deposition of asenapine maleate from the asenapine maleate loaded LNCs:	48
7. Effect of storage on the physical stability of the selected asenapine maleate loaded LNCs.....	50
8. Microscopical examination of the selected asenapine maleate loaded LNCs using high resolution transmission electron microscopy (HR-TEM).....	50
9. Fourier-transform infrared spectroscopy (FTIR)	50
10. Statistical analysis	51
Results and Discussion	52
1. Spectrophotometric scanning of asenapine maleate and determination of wavelength of maximum absorbance (λ_{max}).....	52
2. Calibration curves of asenapine maleate in methanol and in phosphate buffer solution containing 2% Tween 80 pH 7.4 (release media) using UV spectrophotometry	53
3. The Calibration curve of asenapine maleate in phosphate buffer solution pH (7.4) containing 2% Tween 80 (release media) using RP-HPLC assay.....	55
4. Preparation and characterization of blank LNCs	57
4.1. Particle size and PDI.....	60
4.2. Zeta potential	63
5. Preparation and characterization of asenapine maleate loaded LNCs.....	65
5.1. Particle size and PDI.....	67
5.2. Zeta potential	68

5.3. Drug content.....	69
6. <i>Ex vivo</i> skin permeation/deposition study.....	70
7. Effect of storage on the physical stability of asenapine maleate loaded LNCs:	76
8. High resolution transmission electron microscopy (HR-TEM)	77
9. Fourier-transform infrared spectroscopy (FTIR)	78
Conclusions.....	82
Chapter II: Preparation and evaluation of asenapine maleate loaded invasomes.	
Introduction.....	84
Materials and Methods.....	92
Materials:	92
Equipment:	92
Methodology:.....	93
1. Preparation of asenapine maleate loaded invasomes:.....	93
2. Physicochemical characterization of the prepared soft nanovesicles... ..	95
3. Effect of storage on selected asenapine maleate loaded formulations.	96
4. <i>Ex vivo</i> skin permeation/deposition study of the selected asenapine maleate loaded formulations.	96
5. High resolution transmission electron microscopy (HR-TEM)	97
6. Fourier-transform infrared spectroscopy (FTIR)	98
Results and Discussion	99
1. Preparation of asenapine maleate loaded invasomes:.....	99
2. Particle size analysis	99
3. Zeta potential measurements	102
4. Entrapment efficiency.....	102
5. Effect of storage on the physical stability of invasomes:.....	104
6. <i>Ex vivo</i> skin permeation/deposition study.....	106
7. High resolution Transmission electron microscopy (HR-TEM) of the selected invasomes:	109

8. Fourier transform infrared spectroscopy (FTIR):	110
Conclusions.....	113
Chapter III: <i>In vivo</i> studies of selected formulations for the transdermal delivery of asenapine maleate.	
Introduction.....	115
Materials and Methods.....	117
Materials	117
Equipment:	117
Animals.....	118
Methodology.....	118
1. Animals grouping.....	118
2. Construction of asenapine maleate calibration curve in plasma using RP-HPLC analysis.....	120
3. Pharmacokinetic Analysis	121
4. Histological study.....	121
Results and Discussion	123
1. Quantitative analysis of asenapine maleate in plasma samples	123
2. <i>In vivo</i> pharmacokinetic analysis	124
3. Histological evaluation	133
Conclusions.....	134
Future perspective.....	135
Summary	136
References.....	144
Appendix.....	163
الملخص العربى	١

List of Abbreviations

Asenapine maleate	ASPM
Bioavailability	BAV
Differential scanning calorimetry	DSC
Distilled water	DW
Drug loading	DL
Dynamic light scattering	DLS
Reverse phase – High performance liquid chromatography	RP-HPLC
High resolution transmission electron microscopy	HR-TEM
Encapsulation efficiency	EE
Generally regarded as safe	GRAS
Hydrophile lipophile balance	HLB
Labrafac lipophile [®] WL 1349	LL
Lipid nanocapsules	LNCs
Lipid nanoparticles	LNPs
Molecular weight	M _w
Nanoparticles	NPs
Nanostructured lipid carriers	NLCs
Particle size	PS
Phase-inversion temperature	PIT
Phase-inversion zone	PIZ
Phosphate buffered saline	PBS
Polydispersity index	PDI
Surfactant	SAA
Transdermal drug delivery	TDD
Zeta potential	ZP

List of Tables

Table No.	Table Title	Page No.
Table 1	Structural brain changes in schizophrenic patients.	3
Table 2	A list of common symptoms of schizophrenia with brief description.	6
Table 3	First generation antipsychotics available in market with their approval dates and available dosage forms	10
Table 4	Second generation antipsychotics available in market with their approval dates and available dosage forms	11
Table 5	Detailed description of extrapyramidal side effects (EPS) induced by antipsychotics	13
Table 6	Detailed composition of the different blank LNCs	47
Table 7	Detailed composition of different ASPM loaded LNCs	48
Table 8	Relationship between concentration of ASPM and absorbance at λ_{max} 270 nm in methanol	54
Table 9	Relationship between concentration of ASPM and absorbance at λ_{max} 270 nm in phosphate buffer solution pH 7.4 containing 2% Tween 80	55
Table 10	Relationship between ASPM concentrations and the peak areas	57
Table 11	Physical characterization of blank LNCs formulations	59
Table 12	Physical characterization of ASPM*-loaded LNC formulations	67
Table 13	Zeta potential of the different LNCs before and after drug loading	69

Table 14	<i>Ex vivo</i> skin permeation and deposition parameters of asenapine loaded lipid nanocapsules across rat skin	72
Table 15	The effect of storage of the selected ASPM loaded LNCs (F22-AS) on particle size, PDI and zeta potential	77
Table 16	Detailed composition of the different asenapine loaded soft nanovesicles	95
Table 17	Detailed characterization of ASPM loaded soft nanovesicles	100
Table 18	The effect of six months storage of loaded invasomes on particle size, PDI and zeta potential	106
Table 19	<i>Ex vivo</i> skin permeation parameters of ASPM loaded invasomes across rat skin	107
Table 20	Determination of asenapine deposition into rat skin treated with ASPM loaded invasomes post 24 hours.	109
Table 21	Relationship between ASPM plasma concentrations and the peak areas using RP-HPLC	124
Table 22	<i>In vivo</i> pharmacokinetic parameters of transdermal application of optimized ASPM loaded LNCs compared to intravenous and oral route	127
Table 23	<i>In vivo</i> pharmacokinetic parameters of transdermal application of optimized ASPM loaded invasomes compared to intravenous and oral route	132

List of Figures

Figure No.	Figure Title	Page No.
Figure 1	Brain areas involved in the pathophysiology of schizophrenia*	3
Figure 2	Neurotransmission theories involved in pathophysiology of schizophrenia.	5
Figure 3	Electrically-responsive transdermal delivery systems (ETDS)	22
Figure 4	Schematic representation of capsules formed by a tensioactive shell composed by the association of hydrophilic PEGylated surfactant and lipophilic surfactant protecting an oily core (medium chain triglycerides).	27
Figure 5	The structure of invasomes versus liposomes.	30
Figure 6	Formulation steps of Lipid nanocapsules.	35
Figure 7	Chemical Structure of Kolliphor® HS15.	37
Figure 8	Chemical Structure of Kolliphor® EL.	37
Figure 9	Chemical structure of Tween 80.	38
Figure 10	Chemical Structure of Labrafac® PG.	40
Figure 11	Chemical Structure of Labrafil® M1944CS.	40
Figure 12	Chemical Structure of Miglyol® 812.	39
Figure 13	Chemical structure of the main components of lavender oil.	41
Figure 14	Spectrophotometric scanning spectrum of asenapine maleate in methanol.	52
Figure 15	Calibration curve of ASPM at 270 nm in methanol.	54
Figure 16	Calibration curve of ASPM at 270 nm in phosphate buffer solution containing 2% Tween 80.	55
Figure 17	Chromatogram of Asenapine maleate in phosphate buffer solution pH (7.4) containing 2% Tween 80.	56
Figure 18	Calibration curve of ASPM using RP-HPLC assay.	57
Figure 19	The effect of oil type on particle size of LNCs prepared using oil: surfactant ratio 1:1.	61
Figure 20	The effect of surfactant type and oil: surfactant ratio on particle size of LNCs.	62

Figure 21	The Effect of oil: surfactant ratio on zeta potential of LNCs.	63
Figure 22	The effect of ASPM loading on the particle size of LNCs.	67
Figure 23	<i>Ex-vivo</i> skin permeation profiles of asenapine from Labrafil based LNCs across rat skin (n=6).	72
Figure 24	<i>Ex-vivo</i> skin permeation profiles of asenapine from lavender oil based LNCs across rat skin (n=6).	72
Figure 25	The amounts of asenapine permeated per surface area and flux rates of ASPM from the different LNCs.	73
Figure 26	Deposition of asenapine from ASPM loaded LNCs in different skin layers.	75
Figure 27	Visualization of ASPM lipid nanocapsules (F22-AS) showing dense shell and light core.	77
Figure 28	FTIR spectra of drug, excipients, blank and loaded LNCs (F22-AS).	79
Figure 29	The chemical structure of d-limonene.	89
Figure 30	The chemical structure of cineole.	89
Figure 31	The chemical structure of Transcutol®.	90
Figure 32	Effect of penetration enhancer type on particle size of invasomes.	100
Figure 33	Effect of penetration enhancer concentration on entrapment efficiency of invasomes.	103
Figure 34	The effect of six months storage of loaded invasomes on particle size.	105
Figure 35	The effect of six months storage of loaded invasomes on poly dispersity index.	105
Figure 36	<i>Ex-Vivo</i> skin permeation profile of ASPM loaded invasomes through rat abdominal skin (n=6).	106
Figure 37	Deposition of ASPM in skin layers with different invasomes.	108
Figure 38	Visualization of ASPM invasomes containing 1% w/v limonene by transmission electron microscopy.	110
Figure 39	FTIR spectra of drug, excipients, blank and loaded invasomes (F2-AS).	112
Figure 40	Animals grouping	119
Figure 41	Calibration curve of ASPM extracted from plasma samples using RP-HPLC assay.	124
Figure 42	Plasma concentrations of Asenapine after IV, oral and transdermal administration	125